Benicar for blood pressure
Searched over 200M research papers
Summary
8 papers analyzed
These studies suggest that Benicar (olmesartan medoxomil) effectively reduces blood pressure in various patient populations, including those with hypertension, type 2 diabetes, and the elderly, and can be used alone or in combination with other antihypertensive agents.
Not a yes or no question
To use the Consensus Meter, try asking a simple yes or no question
Research summarized with Copilot
Beta20 papers analyzed
Benicar (Olmesartan Medoxomil) for Blood Pressure Management
Introduction to Benicar for Hypertension
Benicar, known generically as olmesartan medoxomil, is an angiotensin II receptor blocker (ARB) approved by the FDA for the treatment of hypertension. It can be used alone or in combination with other antihypertensive agents to manage high blood pressure effectively .
Efficacy of Olmesartan Medoxomil in Blood Pressure Control
24-Hour Blood Pressure Monitoring
Studies have shown that olmesartan medoxomil is highly effective in reducing blood pressure over a 24-hour period. In a study involving patients with hypertension and type 2 diabetes, olmesartan medoxomil, either alone or combined with hydrochlorothiazide (HCTZ), significantly reduced mean 24-hour systolic and diastolic blood pressure by 20.4 mmHg and 11.1 mmHg, respectively. This reduction was consistent throughout the day and night, demonstrating the drug's efficacy in maintaining blood pressure control over a full dosing interval .
Comparison with Other ARBs
Olmesartan medoxomil has been compared with other ARBs such as losartan, valsartan, and irbesartan. It was found to be more effective in reducing blood pressure across various time points, including daytime, nighttime, and the critical last hours of the dosing interval. Patients treated with olmesartan medoxomil achieved higher goal rates for critical ambulatory blood pressure values compared to those treated with losartan or valsartan.
Combination Therapy for Enhanced Efficacy
Elderly Patients with Hypertension
In elderly patients, particularly those with stage 1 and stage 2 hypertension or isolated systolic hypertension (ISH), combination therapy with olmesartan medoxomil and HCTZ has proven to be effective. A study reported significant reductions in mean 24-hour ambulatory blood pressure and seated cuff blood pressure after 12 weeks of treatment. The majority of patients achieved their blood pressure targets, with 88.3% of stage 1 hypertension patients reaching a goal of <140/90 mmHg.
Tribenzor: A Triple Combination Therapy
For patients requiring more intensive blood pressure control, Tribenzor, a combination of olmesartan medoxomil, amlodipine (a calcium channel blocker), and HCTZ, has been approved. This triple combination is recommended for patients not adequately controlled on a two-drug regimen, offering a comprehensive approach to managing hypertension.
Safety and Tolerability
Olmesartan medoxomil is generally well-tolerated with a low incidence of adverse events. In clinical studies, treatment-emergent adverse events were reported in a minority of patients, with drug-related hypotension occurring in less than 3% of cases . This favorable safety profile makes it a viable option for long-term hypertension management.
Conclusion
Olmesartan medoxomil (Benicar) is a potent and effective antihypertensive agent that offers significant blood pressure reductions over a 24-hour period. Its efficacy is enhanced when used in combination with other antihypertensive agents, making it suitable for a wide range of patients, including those with type 2 diabetes and elderly individuals with isolated systolic hypertension. With a strong safety profile, Benicar remains a valuable tool in the management of hypertension.
Sources and full results
Most relevant research papers on this topic
5
New ARB approved for hypertension by the FDA
5
0 Citations
2002
6
Tribenzor for hypertension.
6
0 Citations
2010